WALTHAM, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company, a wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that five abstracts highlighting XERAVA (eravacycline) have been selected for poster presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.
Everest Medicines, a biopharmaceutical company, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China has approved a Clinical Trial Application (CTA) for Xerava (eravacycline) for the treatment of community-acquired bacterial pneumonia (CABP). With this CTA, Everest Medicines plans to conduct a phase 3 trial in China evaluating the efficacy and safety of eravacycline in treating adult patients with CABP.
La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments
BARCELONA, Spain, Oct. 22, 2020 /PRNewswire/ -- SOM Biotech, a biopharmaceutical company specializing in the repositioning of existing drugs for the treatment of diseases with a high unmet need, announces today that it will present in silico and in vitro results regarding Eravacycline for the treatment of SARS-CoV-2 during a virtual poster presentation at the IDWeek 2020 (October 21st – 25th).
SAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline) to treat serious and life-threatening infections, today announced the closing of La Jolla's acquisition of Tetraphase. La Jolla acquired Tetraphase for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights (CVRs). The holders of the CVRs are entitled to receive payments of up to an additional $16.0 million in the aggregate upon the achievement of certain net sales of XERAVA in the United States.
WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections,
In the field of antibiotics, approval is only the first hurdle, the bigger obstacle is always going to be reaping returns in the ‘broken’ market for these life-saving drugs. The long, arduous and expensive path to antibiotic approval typically offers little financial gain as treatments are typically priced cheaply and doctors — confined by hospital budgets — are steered into using older generics in their first response, reserving fresh, more targeted alternatives for acute cases.